In this study, we evaluate the diagnostic values of Cytokeratin 19 fragment (CYFRA21‐1), Fibrin/fibrinogen degradation products (FDP) and CYFRA21‐1 + FDP in bladder cancer, with the objective to expand the application scope of urinary tumor markers in the diagnosis of bladder cancer. This evidence concerns the gene KRT19 and urinary bladder cancer.